

Product Name : Crizotinib

Synonyms : PF-02341066; PF-2341066


Cat No. : M16370

CAS Number : 877399-52-5

Molecular Formula : C₂₁H₂₂Cl₂FN₅O

Formula Weight : 450.34

Chemical Name : 2-Pyridinamine, 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidyl)-1H-pyrazol-4-yl]-



Description : Crizotinib (PF-02341066; PF-2341066) is a potent, selective, orally bioavailable, ATP-competitive inhibitor of c-Met catalytic activity with K_i of 4 nM; displays >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ~40- to 60-fold selective for Tie2, TrkA, and TrkB; also inhibits ALK (IC₅₀=24 nM), potently inhibits c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC₅₀=5-20 nM); shows antitumor efficacy in tumor models at well-tolerated doses in vivo. Lung Cancer Approved

Pathway : Angiogenesis

Target : ALK

Receptor : ALK; c-Met

Solubility : DMSO: 55 mg/mL (Need ultrasonic)

SMILES : C1C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N

Storage : (-20°C)

Stability : ≥ 2 years

Reference :

1. Zou HY, et al. Cancer Res. 2007 May 1;67(9):4408-17. | 2. Christensen JG, et al. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22. | 3. Knowles LM, et al. Clin Cancer Res. 2009 Jun 1;15(11):3740-50.